Overview

Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

Status:
Completed
Trial end date:
2020-07-09
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability and efficacy of AR-1105 (dexamethasone implant) for the treatment of macular edema (ME) due to retinal vein occlusion (RVO). A more durable intravitreal implant containing a low dose of dexamethasone may result in less frequent retreatments, and potentially lower the incidence of steroid-related side effects without compromising efficacy.
Phase:
Phase 2
Details
Lead Sponsor:
Aerie Pharmaceuticals
Treatments:
BB 1101
Dexamethasone
Dexamethasone acetate